⚠ Evidence note: Most trends in this area rest on anecdote and mechanism; where real evidence exists it is usually for narrower claims than the trend makes.
Alpha-Klotho Replacement Therapy
Current understanding
[anecdotal-biohack: trial-announcement signal, not outcome evidence] A first-in-human Phase I trial at GARM Próspera is assessing a single intravenous dose of alpha-Klotho mRNA therapy AKL003 in 20 healthy participants, with safety and exploratory biological-aging endpoints including DNA methylation. [mechanism-plausible] Aging benefit remains a hypothesis; the supplied finding reports no safety or efficacy results.
Evidence log
- 2026-11-12 — Phase I Trial of a Single Administration of aKLmRNA-Mediated Protein Replacement Therapy: cross-connection with longevity-clinics: [anecdotal-biohack] GARM Próspera is the reported trial site for AKL003, connecting the clinic-sector record to investigational alpha-Klotho replacement without establishing clinical benefit. (novelty: 4)
Open questions
Related
Contributing findings
Phase I Trial of a Single Administration of aKLmRNA-Mediated Protein Replacement Therapy
12-nov-2026
novelty 4
per-area 4
introduces